Journal of Oncology / 2021 / Article / Tab 1

Research Article

Comparative Recurrence Analysis of Pancreatic Adenocarcinoma after Resection

Table 1

Clinicopathological characteristics of patients with PDAC stratified by tumor site.

CharacteristicsTumor siteCharacteristicsTumor site
HeadBody/tailNHeadBody/tailN

Whole cohort24755302Macrovascular invasionAbsence23142273<0.001
Age≤60 years140241640.099Presence161329
>60 years10731138Microvascular invasionAbsence162442060.039
GenderMale97221191.000Presence851196
Female15033183Lymph vessel invasionAbsence125151400.031
RecurrenceAbsence148261740.098Presence12240162
Presence9929128Perineural invasionAbsence127191460.026
Time to recurrenceAbsence111181290.211Presence12036156
2–6 M541872Adjacent organ invasionAbsence24723270<0.001
6–12 M461157Presence03232
12–24 M23326LNR0135381730.140
>24 M135180–0.1658866
Recurrence patternsAbsence148261740.157>0.1654963
Local32739Satellite fociAbsence24344287<0.001
Liver-only391049Presence41115
Lung-only8412TNM stageIA49554<0.001
Other sites235IB641074
Local + distant11314IIA221335
Multiple729IIB71879
LN metastasisAbsence136381740.070III411960
Presence11117128Imaging tumor size (cm)≤2977104<0.001
LN5 metastasisAbsence245553001.0002–412318141
Presence202>4273057
LN6 metastasisAbsence243552981.000Imaging LN metastasisAbsence133421750.002
Presence404Presence11413127
LN7 metastasisAbsence242542961.000Imaging vascular invasionAbsence20925234<0.001
Presence516Presence383068
LN8 metastasisAbsence241532940.641Imaging LN size (cm)≤0.5139381770.216
Presence6280.5–155964
LN9 metastasisAbsence239532921.000>153861
Presence8210PI0154451990.022
LN10 metastasisAbsence24748295<0.001176884
Presence077217219
LN11 metastasisAbsence24747294<0.001NLR≤3.32153441970.012
Presence088>3.329411105
LN12 metastasisAbsence213552680.001dNLR≤3.3279211000.429
Presence34034>3.3216834202
LN13 metastasisAbsence178532310.001PLR≤98.13211536<0.001
Presence69271>98.1322640266
LN14 metastasisAbsence227542810.141PNI05411650.857
Presence2012111934437
LN15 metastasisAbsence241532940.641SII≤1000158482060.001
Presence628>100089796
LN16 metastasisAbsence231532840.544mGPS0157452020.033
Presence16218160767
LN17 metastasisAbsence238552930.373230333
Presence909WBC≤10227532800.389
LN18 metastasisAbsence244522960.076>1020222
Presence336ALB (g/L)≤35433460.023
Positive LN number0135381730.142>3520452256
1–3831295CRP (ng/L)≤3157452020.011
>429534>39010100
Pancreatic membrane invasionAbsence16320183<0.001CA19-9 (U/ml)≤354910590.853
Presence8435119>3519845243
Tumor size (cm)≤282688<0.001CEA (ng/ml)≤5172332050.201
2–412521146>5752297
>4402868HBV infectionAbsence229542830.216
Tumor differentiationWell0220.010Presence18119
Moderate12528153ChemotherapyNo134261600.373
Poor12225147Yes11329142
HemorrhageAbsence241542950.626Biliary fistulaAbsence212472590.543
Presence617Presence35843
Pancreatic fistulaAbsence193482410.141Abdominal infectionAbsence225542790.091
Presence54761Presence22123

M, month; LN, lymph node metastasis; LNR, lymph node ratio; TNM, tumor-node-metastasis stage; PI, prognostic index; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; PNI, prognostic nutritional index; SII, systemic immune-inflammation index; mGPS, modified Glasgow Prognostic Score; WBC, white blood cell count; ALB, albumin; CRP, C-reactive protein; CA19-9, carbohydrate antigen 19–9; CEA, carcinoembryonic antigen; HBV, hepatitis B virus.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.